BioTuesdays

Category - Markets

JMP resumes coverage of Novadaq at outperform

JMP Securities has resumed coverage of Novadaq Technologies (NASDAQ:NVDQ; TSX:NDQ) with a “market outperform” rating and $16 price target. The stock closed at $13.50 on Tuesday.“Novadaq was once highly regarded within...

Cynosure

Stifel ups Cynosure price target to $50

Stifel has raised its price target for Cynosure (NASDAQ:CYNO) to $50 from $44, reflecting revised estimates and an increased sales multiple due to the company’s higher growth rate. The stock closed at $42 on Monday...

Prima BioMed

Roth starts Prima BioMed at buy

Roth Capital Partners has initiated coverage of Prima BioMed (NASDAQ:PBMD) with a “buy” rating and price target of $6. The stock closed at $1.11 on Wednesday. “We believe Prima is in a leading position in the...

Roth starts TetraLogic Pharma at buy

Roth Capital Partners has launched coverage of TetraLogic Pharmaceutics (NASDAQ:TLOG) with a “buy” rating and price target of $5. The stock closed at $1.42 on Wednesday.Analyst Joseph Pantginis writes that TetraLogic is...

oramed

Oramed closes licensing, investment deal in China

Oramed Pharmaceuticals (NASDAQ:ORMP) has closed a license and investment deal with Hefei Tianhui Incubation of Technologies (HTIT) of China. Oramed has sold 1,155,367 restricted common shares to HTIT at a price of $10...

Adamas Pharmaceuticals

WB ups Adamas Pharma price target to $42

William Blair has raised its price target on Adamas Pharmaceuticals (NASDAQ:ADMS) to $42 from $35 after the company announced positive top-line results from its Phase 3 EASE LID trial with lead candidate ADS-5102...

fibrocell

Roth starts Fibrocell Science at buy

Roth Capital Partners has initiated coverage of Fibrocell Science (NASDAQ:FCSC) with a “buy” rating and 12-month target price of $14. The stock closed at $5.28 on Monday. “Leaning on 20 years of experience with...

Relypsa

HCW starts Relypsa at buy

H.C. Wainwright has initiated coverage of Relypsa (NASDAQ:RLYP) with a “buy” rating and price target of $63. The stock closed at $28.31 on Wednesday. “We believe [Relypsa’s] Veltassa is well positioned to address the...

OraSure Technologies

BTIG starts OraSure Technologies at buy

BTIG has launched coverage of OraSure Technologies (NASDAQ:OSUR) with a “buy” rating and price target of $8. The stock closed at $6.19 on Friday. “A profitable small-cap diagnostics company is a rare find,” writes...

Subscribe

Sign up to our weekly BioTuesdays newsletter.